期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 14, 期 9, 页码 1017-1021出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2008.06.013
关键词
polifermin; GVHD; hematopoietic stem cell transplantation
资金
- National Institutes of Health [R01 HL073794, P01 CA03952, 2P30CA046592]
- Food and Drug Administration [FRD 020201]
We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 mu g/kg to 720 mu g/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients. Treatment with palifermin showed beneficial effects on mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconstitution, have been seen in experimental transplant models. Therefore, we investigated whether with longer follow-up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients. (C) 2008 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据